Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,463,120

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 4:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Charles River's (CRL) New Launch to Boost Gene Therapy Workflow

by Zacks Equity Research

Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.

Snehadri Nag headshot

4 Defensive Bets to Pacify Pessimists to Ride Market Storms

by Snehadri Nag

Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water, McKesson and Hershey with strong prospects to stay afloat in the bear market.

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.

McKesson (MCK) Stock Moves -1.2%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed at $346.68 in the latest trading session, marking a -1.2% move from the prior day.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips

by Zacks Equity Research

Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.

    Here's Why You Should Retain Inari Medical (NARI) Stock Now

    by Zacks Equity Research

    Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

    SmileDirectClub (SDC) Hurt by Lower Spending, Margin Woe

    by Zacks Equity Research

    The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.

      Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval

      by Zacks Equity Research

      Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.

      Zacks Investment Ideas feature highlights: Molina Healthcare, McKesson and Humana

      by Zacks Equity Research

      Molina Healthcare, McKesson and Humana are part of the Zacks Investment Ideas article.

      Derek Lewis headshot

      3 Top-Ranked Healthcare Stocks Thriving in 2022

      by Derek Lewis

      Healthcare stocks generally carry a defensive nature, helping to shield investors from the market's volatility. Demand for the services these companies provide won't be going anywhere anytime soon.

      Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist

      by Zacks Equity Research

      Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.

        3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

        by Zacks Equity Research

        Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

          Veeva Systems' (VEEV) Latest Launches to Enhance Workflow

          by Zacks Equity Research

          Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.

          McKesson (MCK) Stock Moves -1.99%: What You Should Know

          by Zacks Equity Research

          McKesson (MCK) closed the most recent trading day at $342, moving -1.99% from the previous trading session.

          Merit Medical (MMSI) Launches New Soft Tissue Biopsy System

          by Zacks Equity Research

          Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.

          Zacks.com featured highlights include Hyatt Hotels, McKesson and Carlsberg

          by Zacks Equity Research

          Hyatt Hotels, McKesson and Carlsberg are part of Zacks Screen of the Week article.

          PacBio's (PACB) New Method for TR Profiling Now Available

          by Zacks Equity Research

          PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.

          3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio

          by Zacks Equity Research

          Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

          Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

          by Zacks Equity Research

          The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.